MX2018014771A - Oligonucleotidos que comprenden nucleosidos modificados. - Google Patents
Oligonucleotidos que comprenden nucleosidos modificados.Info
- Publication number
- MX2018014771A MX2018014771A MX2018014771A MX2018014771A MX2018014771A MX 2018014771 A MX2018014771 A MX 2018014771A MX 2018014771 A MX2018014771 A MX 2018014771A MX 2018014771 A MX2018014771 A MX 2018014771A MX 2018014771 A MX2018014771 A MX 2018014771A
- Authority
- MX
- Mexico
- Prior art keywords
- oligonucleotides
- modified nucleosides
- position modified
- aptamers
- polynucleotides
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 125000003835 nucleoside group Chemical group 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 3
- 108091023037 Aptamer Proteins 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
- C12N2330/31—Libraries, arrays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/117—Modifications characterised by incorporating modified base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/205—Aptamer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pathology (AREA)
Abstract
Se proporcionan polinucleótidos, tales como aptámeros, que comprenden al menos una primera pirimidina modificada en la posición 5 y al menos una segunda pirimidina modificada en la posición 5, en donde la primera y la segunda pirimidinas modificadas en la posición 5 son diferentes. También se proporcionan métodos para seleccionar y usar los polinucleótidos, tales como aptámeros.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357623P | 2016-07-01 | 2016-07-01 | |
| US201662437592P | 2016-12-21 | 2016-12-21 | |
| PCT/US2017/040299 WO2018005974A1 (en) | 2016-07-01 | 2017-06-30 | Oligonucleotides comprising modified nucleosides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014771A true MX2018014771A (es) | 2019-04-25 |
Family
ID=59351104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014771A MX2018014771A (es) | 2016-07-01 | 2017-06-30 | Oligonucleotidos que comprenden nucleosidos modificados. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10927380B2 (es) |
| EP (2) | EP3478843B1 (es) |
| JP (2) | JP7203613B2 (es) |
| KR (2) | KR102501963B1 (es) |
| CN (1) | CN109312346B (es) |
| AU (1) | AU2017290804B2 (es) |
| BR (1) | BR112018075869A8 (es) |
| CA (1) | CA3027626A1 (es) |
| DK (1) | DK3478843T3 (es) |
| ES (1) | ES2886639T3 (es) |
| IL (3) | IL291931B2 (es) |
| MX (1) | MX2018014771A (es) |
| PL (1) | PL3478843T3 (es) |
| RU (2) | RU2021137915A (es) |
| SG (2) | SG10201911369PA (es) |
| TW (1) | TWI770036B (es) |
| WO (1) | WO2018005974A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021202376A1 (en) | 2020-03-30 | 2021-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs |
| US11866711B2 (en) | 2020-08-28 | 2024-01-09 | Galderma Holding SA | X-aptamers for the use in detection of SNAP25 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US5719273A (en) * | 1993-06-14 | 1998-02-17 | Nexstar Pharmaceuticals, Inc. | Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide |
| US5945527A (en) * | 1996-05-30 | 1999-08-31 | Nexstar Pharmaceuticals, Inc. | Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide |
| US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
| WO2003078623A1 (fr) | 2002-03-19 | 2003-09-25 | Fujitsu Limited | Molecule fonctionnelle et son procede de production |
| EP2952894B1 (en) | 2006-01-17 | 2017-08-30 | Somalogic, Inc. | Kits comprising aptamers |
| ZA200903562B (en) | 2006-11-14 | 2010-07-28 | Ribomic Inc | Aptamer against midkine and use thereof |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US7855054B2 (en) | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
| JP5750209B2 (ja) | 2007-03-16 | 2015-07-15 | アプタ バイオサイエンス リミテッド | 機能性分子、機能性分子合成用アミダイド、及び標的物質解析方法 |
| EP2069496A4 (en) | 2007-07-17 | 2010-01-27 | Somalogic Inc | SELEX AND PHOTOSELEX ENHANCED |
| JP5195757B2 (ja) | 2007-08-31 | 2013-05-15 | 富士通株式会社 | 核酸合成用ダイマーアミダイド及び核酸合成方法 |
| JP4499141B2 (ja) | 2007-09-05 | 2010-07-07 | 富士通株式会社 | 修飾核酸合成用アミダイド及び修飾核酸合成方法 |
| RU2401306C2 (ru) | 2008-12-17 | 2010-10-10 | Научно-исследовательский институт Физико-химической биологии имени А.Н. Белозерского Московского Государственного Университета имени М.В. Ломоносова | Аптамерный олигонуклеотид - прямой ингибитор тромбина |
| US8569252B2 (en) * | 2009-04-15 | 2013-10-29 | Postech Academy-Industry Foundation | Nucleolin specific aptamer and use thereof |
| AU2011223527B2 (en) | 2010-03-03 | 2014-11-13 | Somalogic Operating Co., Inc. | Aptamers to 4-1BB and their use in treating diseases and disorders |
| WO2012122540A1 (en) * | 2011-03-10 | 2012-09-13 | Somalogic, Inc. | Aptamers for clostridium difficile diagnostics |
| WO2013149086A1 (en) | 2012-03-28 | 2013-10-03 | Somalogic, Inc. | Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions |
| JP6591392B2 (ja) | 2013-03-14 | 2019-10-16 | ソマロジック, インコーポレイテッドSomaLogic, Inc. | Ｉｌ−６に結合するアプタマー及びｉｌ−６介在性状態の治療または診断におけるそれらの使用 |
| KR102348283B1 (ko) | 2013-09-24 | 2022-01-10 | 소마로직, 인크. | 멀티앱타머 표적 검출 |
| RU2658363C2 (ru) | 2013-10-11 | 2018-06-21 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Водные гербицидные концентраты |
| AU2014353102B2 (en) * | 2013-11-21 | 2019-05-16 | Somalogic Operating Co., Inc. | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto |
| ES2764669T3 (es) | 2014-02-18 | 2020-06-04 | Somalogic Inc | Composiciones y métodos para la detección de microorganismos |
| WO2015153860A1 (en) * | 2014-04-04 | 2015-10-08 | Somalogic, Inc. | Glomerular filtration rate biomarkers and uses thereof |
| NO2718257T3 (es) * | 2014-05-30 | 2018-04-14 | ||
| US20170335395A1 (en) | 2014-10-27 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | A parkinson's disease diagnostic biomarker panel |
| AU2015353767B2 (en) * | 2014-11-24 | 2021-09-09 | Somalogic Operating Co., Inc. | Nucleic acid compounds for binding growth differentiation factor 11 |
-
2017
- 2017-06-30 RU RU2021137915A patent/RU2021137915A/ru unknown
- 2017-06-30 RU RU2019102588A patent/RU2763470C2/ru active
- 2017-06-30 ES ES17740201T patent/ES2886639T3/es active Active
- 2017-06-30 EP EP17740201.3A patent/EP3478843B1/en active Active
- 2017-06-30 WO PCT/US2017/040299 patent/WO2018005974A1/en unknown
- 2017-06-30 BR BR112018075869A patent/BR112018075869A8/pt unknown
- 2017-06-30 AU AU2017290804A patent/AU2017290804B2/en active Active
- 2017-06-30 SG SG10201911369PA patent/SG10201911369PA/en unknown
- 2017-06-30 EP EP21174810.8A patent/EP3913058A1/en active Pending
- 2017-06-30 DK DK17740201.3T patent/DK3478843T3/da active
- 2017-06-30 IL IL291931A patent/IL291931B2/en unknown
- 2017-06-30 SG SG11201811199QA patent/SG11201811199QA/en unknown
- 2017-06-30 CN CN201780036021.0A patent/CN109312346B/zh active Active
- 2017-06-30 CA CA3027626A patent/CA3027626A1/en active Pending
- 2017-06-30 IL IL311294A patent/IL311294A/en unknown
- 2017-06-30 PL PL17740201T patent/PL3478843T3/pl unknown
- 2017-06-30 US US16/307,520 patent/US10927380B2/en active Active
- 2017-06-30 TW TW106121878A patent/TWI770036B/zh active
- 2017-06-30 JP JP2018566956A patent/JP7203613B2/ja active Active
- 2017-06-30 KR KR1020187036330A patent/KR102501963B1/ko active IP Right Grant
- 2017-06-30 KR KR1020237005478A patent/KR20230031972A/ko not_active Application Discontinuation
- 2017-06-30 MX MX2018014771A patent/MX2018014771A/es unknown
-
2018
- 2018-12-20 IL IL263852A patent/IL263852B/en unknown
-
2020
- 2020-12-18 US US17/126,330 patent/US11578330B2/en active Active
-
2022
- 2022-12-27 JP JP2022209677A patent/JP7531574B2/ja active Active
-
2023
- 2023-01-12 US US18/153,428 patent/US20230313202A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273341A (en) | Converted nucleosides, nucleotides and their analogs | |
| SG10202111808WA (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| BR112017025986A2 (pt) | inibidores de tirosina quinase de bruton. | |
| MA43162A (fr) | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton | |
| MX2021015826A (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| WO2015051173A3 (en) | Polynucleotide molecules and uses thereof | |
| EP3430000A4 (en) | PYRIMIDINES AND VARIANTS THEREOF AND USES THEREOF | |
| MX2016003320A (es) | Deteccion objetivo de multiples aptameros. | |
| PH12018500736A1 (en) | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity | |
| EP3433258A4 (en) | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREOF | |
| ZA201701131B (en) | Novel 2,5-substituted pyrimidines as pde4 inhibitors | |
| IL250426A0 (en) | 2'-Chloro aminopyrimidinone and pyridine dione nucleosides | |
| IL279886A (en) | Engineered variant purine nucleoside phosphorylase enzymes | |
| HK1257799A1 (zh) | 6-取代的吡啶並[2，3-d]嘧啶類化合物作為蛋白激酶抑制劑 | |
| GB2552269B (en) | Substituted pyrrolo(2,3-D)pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors | |
| TWD178776S (zh) | 行李箱（一） | |
| MX2018014771A (es) | Oligonucleotidos que comprenden nucleosidos modificados. | |
| EP3418289A4 (en) | ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE AND ARTIFICIAL OLIGONUCLEOTIDE | |
| EP3744726A4 (en) | NEW NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES AND THEIR USES | |
| HUE057596T2 (hu) | Spirotietán nukleozidok | |
| PE20180503A1 (es) | 2-tiopirimidinonas | |
| MX2023012081A (es) | Nucleosidos modificados. | |
| HK1256227A1 (zh) | 修飾的核苷或核苷酸 | |
| UA123593U (uk) | 2-(7-ФУРАН-21-ІЛ-2-МОРФОЛІН-41-ІЛ-4-ОКСО-4Н-ТІАЗОЛО[4,5-d]ПІРИДАЗИН-5-ІЛ)-N-НАФТАЛІН-1-ІЛАЦЕТАМІД, ЩО МАЄ ПРОТИПУХЛИННУ АКТИВНІСТЬ | |
| SI3621966T1 (sl) | Derivati pirazol(1,5-A)pirimidina kot kinazni JAK inhibitorji |